International Stroke Conference 2024 to Present High-Profile Late-Breaking Science

January 23, 2024 — Focused on delivering the latest scientific advancements and new treatments in cerebrovascular diseases and brain health science from around the world, this year's International Stroke Conference, ISC 2024, will be held Feb. 7-9 in Phoenix, Arizona. According to the American Stroke Association, a division of the American Heart Association, findings from Late-Breaking Science will include multiple high profile randomized cardiovascular clinical trials like RESILIENT-Extend, EMBOLISE, STEM, ZODIAC, among many others.

Program planners are putting final details on this year’s offerings, reinforcing the opportunities for collaboration and engagement with thought leaders in the field, and the vast network of professionals collaborating towards understanding stroke pathophysiology, developing effective therapies and exploring brain health and stroke recovery with an array of specialized and compelling topics.

Late-Breaking Science sessions and concurrent oral abstract presentations are as follows:

Wed., Feb. 7

ZODIAC Zero Degree Head Positioning in Acute Large Vessel Ischemic Stroke:
Anne Alexandrov, University of Tennessee Health Science Center, Memphis, TN

RESILIENT-Extend Randomization of Endovascular Treatment with Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke due to Large VEssel OcclusioN Trial in the Extended Time Window:
Raul Nogueira, University of Pittsburgh, Pittsburgh, PA

MOST Multi-Arm Optimization of Stroke Thrombolysis Trial:
Opeolu Adeoye, Washington University, Saint Louis, MO

Thurs., Feb. 8

TREND Intravenous Tirofiban Reduces Early Neurological Deterioration in Acute Ischemic Stroke: The Trend Randomized Controlled Clinical Trial:
Zhao Wenbo, Xuanwu Hospital, Beijing, China

Uric Acid Supplementation Provides Cerebroprotection Across Different Animal Species, Sex, Age and Comorbidities: A Report from the Stroke Preclinical Assessment Network (SPAN):
Rakesh Patel, University of Iowa, Iowa City, IA

Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz: A Phase III Trial:
Sun U. Kwon, Asan Medical Center, Seoul, Korea

Golden Bridge II Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients With Acute Ischemic Stroke : A Cluster-Randomized Clinical Trial:
Zixiao Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Friday, Feb. 9

EMBOLISE Embolization of the Middle Meningeal Artery With OnyxTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma:
Jason Michael Davies, University at Buffalo, Buffalo, NY

MAGIC-MT: The MAGIC-MT Trial: Managing Non-Acute Subdural Hematoma Using Liquid Materials: A Chinese Randomized Trial of Middle Meningeal Artery Treatment:
Ying Mao, Huashan Hospital, Fudan University, Shanghai, China

STOP-CAD: Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study:
Shadi Yaghi, Brown University, Providence, RI;

STEM: The Squid Trial for the Embolization of the MMA for the treatment of CSDH:
Adam Arthur, Semmes-Murphey Neurological Clinic, Memphis, TN

Delayed Therapy with Humanized Anti-Sdc2 mAb Prevents Formation of Vasogenic Edema and Promotes Neuroprotection in Non-Human Primates with Ischemic Stroke:
Federico Corti, PhD, Yale University, New Haven, CT

CHABLIS-II: LB33. Tenecteplase Thrombolysis for Stroke Up to 24 Hours After Onset with Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial:
Xin Cheng, Huashan Hospital Fudan University, Shanghai, China

Machine Learning Algorithms for Autonomous Detection of Stroke Symptoms and Bell's Palsy:
Radoslav Raychev, MD, UCLA Health, Los Angeles, CA

RAISE: Reteplase Treating Patients with Acute Ischemic Stroke (RAISE): A Phase 3, Multi-Centre, Open-Label, Randomised Controlled, Non-Inferiority Trial:
Yongjun Wang, Beijing Tiantan Hospital, Beijing, China

INSPIRES: Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke or Transient Ischemic Attack: The INSPIRES Randomized Clinical Trial:
Yuesong Pan, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

SELECT2: Long-Term Outcomes and EVT Treatment Effect From Randomized Controlled Trial of Endovascular Thrombectomy for Large Ischemic Strokes:
Amrou Sarraj, MD, University Hospital Cleveland Medical, Cleveland, OH

Late-Breaking Oral Abstracts

The following late-breaking oral abstracts will be presented concurrently at ISC 2024:

Wed., Feb. 7

Late-Breaking Science Oral Abstracts I (beginning at 2:00 p.m. MT)

TESLA: The Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke Trial: 1-Year Outcome:
Osama Zaidat, MD, Mercy Health St. Vincent's Hospital, Toledo, OH

Twin2Win: A Randomized Study to Compare the Efficacy of Primary Dual-Stent Retriever vs. Primary Single-Stent Retriever Technique:
Marc Ribo, Hospital Vall d Hebron, Barcelona, Spain

RESCUE: A Randomized, Blinded Placebo-controlled, Parallel Group Trial to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy:
Supurna Ghosh, Revalesio, Tacoma, WA

A Novel Artificial Intelligence Method to Measure Functional Outcomes in Rodents: A Report from the Stroke Preclinical Assessment Network (SPAN):
Mariia Kumskova, University of Iowa, Iowa City, IA

Late-Breaking Science Oral Abstracts II (beginning at 4:45 p.m. MT)

Outcomes of Patients with Endovascular Thrombectomy in the Multi-Arm Optimization of Stroke Thrombolysis Trial:
Colin Derdeyn, University of Iowa, Iowa City, IA

Subgroup Analysis of Fasudil Efficacy in the Multi-Laboratory Stroke Preclinical Assessment Network Trial:
Takahiko Imai, PharmD, PhD, Harvard Medical School, Massachusetts General Hospital, Boston, MA

Tenecteplase versus Alteplase for Acute Ischemic Stroke in the Oldest-Old Patients:
Yunyun Xiong, Beijing Tiantan Hospital, Beijing, China

Fibrinogenase for Injection in the Treatment of Acute Ischemic Stroke: A Randomized Double Bline and Placebo Controlled Study:
Xin Jiang, West China Hospital, Sichuan University, Chengdu, China

Thurs., Feb. 8

Late-Breaking Science Oral Abstracts III (beginning at 2:00 p.m. MT)

Infarct Size and Estimated Treatment Effect of Early versus Late Anticoagulation After Ischemic Stroke in People with Atrial Fibrillation:
Urs Fischer, MD, University Hospital Basel, Basel, Switzerland

ARCADIA: Anticoagulation for Prevention of Silent Infarct in the ARCADIA Trial:
Maarten Lansberg, MD, PhD, Stanford University, Palo Alto, CA

Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis Triggers Intracerebral Hemorrhage in Mutant KRAS-Induced Brain Arteriovenous Malformations:
Hyejin Park, The University of Texas Health Science Center at Houston, Houston, TX

Secondary Analyses to Optimize Response to Andexanet from ANNEXa-1:
Ashkan Shoamanesh, McMaster University/Population Health Research Institute, Hamilton, ON

Late-Breaking Science Oral Abstracts IV (beginning at 3:30 p.m. MT)

Lipid Accumulation in Mouse and Human Peripheral Blood Leukocytes After Ischemic Stroke and Its Correlation to Functional Outcome:
Trang Do, UTHealth Houston- McGovern Medical, Houston, TX

Impact of Stenosis Degree on the Efficacy of Stenting versus Medical Therapy Alone for Symptomatic Intracranial Stenosis: A Preplanned Pooled Analysis of Individual Patient Data:
Tao Wang, Xuanwu Hospital, Beijing China

INSPIRES: Dual Antiplatelet Therapy in Patients with Multiple Acute Infarctions of Atherosclerotic Origin: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial:
Yilong Wang, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

TIMELESS: Subgroup Analyses from the TIMELESS Trial:
Gregory Albers, MD, Stanford University, Palo Alto, CA

Late-Breaking Science Oral Abstracts V (beginning at 4:45 p.m.)

Impact of COVID-19 Vaccine on Cerebrovascular Health: A Prospective Community-Based Study:
Yiu ming bonaventure IP, The Chinese University of Hong Kong, Hong Kong, Hong Kong

ARCADIA: Atrial Cardiopathy Biomarkers and Atrial Fibrillation in the ARCADIA Trial:
Hooman Kamel, MD, MS, Weill Cornell Medicine, New York, NY

Fingolimod as a Potential Cerebroprotectant Results from the Stroke Preclinical Assessment Network (SPAN):
Ligia Boisserand, PhD, Yale University, New Haven, CT

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and First 900 Subjects:
Steven Greenberg, MD, PhD, Massachusetts General Hospital, MGH, Boston, MA

For more information: www.heart.org; www.stroke.org